Why the study?
Do new oral anticoagulants (NOACs) improve efficacy and reduce bleeding compared to vitamin K antagonists in patients with acute venous thromboembolism?
Population
27,024 patients with acute venous thromboembolism included in the RE-COVER, RE-COVER II, EINSTEIN DVT and…
Comparison
New oral anticoagulants including dabigatran… vs Vitamin K antagonists (VKAs)
Design
Systematic_review
Authors
Loading...
Supports preferential use of rivaroxaban or apixaban over VKA in acute VTE to reduce bleeding; reinforces Level 1 evidence for NOAC-first strategies.
Do new oral anticoagulants (NOACs) improve efficacy and reduce bleeding compared to vitamin K antagonists in patients with acute venous thromboembolism?
NOACs are as effective as VKAs for treating acute VTE but offer a significantly reduced risk of bleeding complications, with indirect comparisons suggesting apixaban may have the most favorable bleeding profile.
Hirschl et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: